Earlier this month, Rhythm Pharmaceuticals received U.S. FDA approval to expand IMCIVREE (setmelanotide) to adults and children 4 years and older with acquired hypothalamic obesity, supported by ...
The $20 billion ceiling contract with the Army shows a new pattern: that VC‑backed platforms can win prime‑like enterprise deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results